The therapeutic ratio is preserved for radiotherapy or cisplatin treatment in BRCA2-mutated prostate cancers

Danny Vesprini, Steven A. Narod, John Trachtenberg, Juanita Crook, Farid Jalali, John Preiner, Srikala Sridhar, Robert G. Bristow

Research output: Contribution to journalArticlepeer-review

Abstract

Prostate cancers in patients with a mutation in BRCA2 have earlier disease onset and an aggressive course, often necessitating the use of systemic therapy. However, these tumours are DNA repair-defective and could respond favourably to Parp inhibitors or DNA-damaging agents, depending on the therapeutic ratio (ratio of tumour response to normal tissue toxicity). We describe 3 patients treated with precision radiotherapy or cisplatin who responded favourably to both agents, yet did not suffer undue toxicity. We review the concept of treating such patients with agents that are selectively toxic to repair-deficient tumours.

Original languageEnglish
Pages (from-to)E31-E35
Number of pages5
JournalJournal of the Canadian Urological Association
Volume5
Issue number2
DOIs
Publication statusPublished - Apr 2011

Research Beacons, Institutes and Platforms

  • Manchester Cancer Research Centre

Fingerprint

Dive into the research topics of 'The therapeutic ratio is preserved for radiotherapy or cisplatin treatment in BRCA2-mutated prostate cancers'. Together they form a unique fingerprint.

Cite this